Compare AbbVie Inc (ABBV) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs ABRDN Physical Gold Shares ETF — how do they compare? AbbVie Inc trades at $248.44 (market cap $441.94B), while ABRDN Physical Gold Shares ETF trades at $42.05. The key difference: AbbVie Inc pays a 2.77% dividend while ABRDN Physical Gold Shares ETF pays none, and AbbVie Inc is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | SGOL | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $263.58 | $51.41 |
52-Week Low | $197.38 | $31.61 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $248.40, up 0.2% with a bullish technical signal supported by moving averages. The company demonstrates strong revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying activity highlight ongoing momentum. Valuation ratios appear elevated with a P/E of 70.65 and P/B of 245.29, reflecting premium pricing for its pharmaceutical pipeline.
Outlook remains positive with 70.7% analyst buy ratings and a $278.69 consensus target offering 12% upside. Key risks include patent expirations, regulatory challenges from drug pricing lawsuits, and high debt levels. The dividend aristocrat status and robust immunology portfolio position ABBV for sustained growth, though investors should monitor execution against lofty 2026 EPS expectations of $3.87 for Q3.
SGOL, a US-listed gold ETF, trades at $41.91, up 0.26% today, with a bullish technical signal from moving averages but bearish oscillators. Recent news highlights gold's strength amid cooling US inflation and central bank demand, with spot gold reaching $4,438/oz on August 12, 2026. The ETF lacks fundamental ratios like P/E and P/B, as it tracks physical gold, not a company with earnings.
The outlook for SGOL is positive, driven by gold's safe-haven appeal and supportive macroeconomic factors, but risks include Fed policy shifts and gold price volatility. Analyst sentiment is mixed, with technical indicators suggesting caution near overbought levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
